quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:00:00·91d
PRRelease
Protara Therapeutics Inc. logo

Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium

TARA· Protara Therapeutics Inc.
Health Care
Original source

Companies

  • TARA
    Protara Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Mar 4UpdateAnalyst$27.00
  • Jan 7UpdatePiper Sandler$24.00
  • Apr 16UpdateScotiabank$12.00
  • Mar 14UpdateCantor Fitzgerald-
  • Jul 10UpdateGuggenheim$22.00
  • Nov 8UpdateOppenheimer$34.00

Related

  • SEC6d
    SEC Form PRE 14A filed by Protara Therapeutics Inc.
  • INSIDER14d
    SEC Form 4 filed by Zummo Jacqueline
  • INSIDER21d
    SEC Form 4 filed by Zummo Jacqueline
  • SEC24d
    Protara Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure
  • SEC44d
    SEC Form 10-K filed by Protara Therapeutics Inc.
  • SEC44d
    Protara Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • PR44d
    Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
  • SEC48d
    SEC Form 424B7 filed by Protara Therapeutics Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022